First-line sunitinib plus FOLFIRI in Japanese patients with unresectable/metastatic colorectal cancer: A phase II study

A phase I study of sunitinib in combination with FOLFIRI in patients with untreated metastatic colorectal cancer

(2011) N. Starling et al.   ANNALS OF ONCOLOGY

Prospective Phase II Study of FOLFIRI for mCRC in Japan, Including the Analysis of UGT1A1*28/*6 Polymorphisms

(2011) Y. Okuyama et al.   JAPANESE JOURNAL OF CLINICAL ONCOLOGY

Regimen Selection for First-line FOLFIRI and FOLFOX Based on UGT1A1 Genotype and Physical Background is Feasible in Japanese Patients with Advanced Colorectal Cancer

(2011) H. Ishida et al.   JAPANESE JOURNAL OF CLINICAL ONCOLOGY

Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors

(2011) Eric Raymond et al.   NEW ENGLAND JOURNAL OF MEDICINE

UGT1A1*1/*28 and *1/*6 genotypes have no effects on the efficacy and toxicity of FOLFIRI in Japanese patients with advanced colorectal cancer

(2010) Yu Sunakawa et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis

(2009) Brett E. Houk et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Phase IV Study of Bevacizumab in Combination with Infusional Fluorouracil, Leucovorin and Irinotecan (FOLFIRI) in First-Line Metastatic Colorectal Cancer

(2009) Alberto Sobrero et al.   ONCOLOGY

Overview of Systemic Therapy for Colorectal Cancer

(2009) Rachel Goodwin et al.   Clinics in Colon and Rectal Surgery

Safety of irinotecan and infusional fluorouracil/leucovorin (FOLFIRI) in Japan: a retrospective review of 48 patients with metastatic colorectal cancer

(2008) Nozomu Fuse et al.   International Journal of Clinical Oncology